Key Benefits

• Check for fatty liver and linked heart risk in a simple panel.
• Spot silent liver stress early using ALT, AST, and GGT.
• Clarify patterns: higher ALT than AST favors NAFLD; reverse may flag fibrosis.
• Quantify heart risk and guide therapy using LDL and ApoB; AIP refines.
• Explain metabolic drivers of liver fat using triglycerides and HDL balance.
• Protect fertility and pregnancy by flagging NAFLD-linked risks like gestational diabetes.
• Track progress as ALT, GGT, triglycerides, and ApoB improve with weight loss.
• Best interpreted with waist size, HbA1c, blood pressure, and liver imaging.

What are NAFLD Biomarkers?

NAFLD biomarkers are measurable signals from your blood that offer a noninvasive window into liver health. They reflect three core processes: how much fat is stored in the liver (hepatic steatosis), whether liver cells are being damaged and dying (hepatocellular injury and apoptosis), and whether scar tissue is building up (fibrosis). Some come directly from stressed or injured liver cells, such as liver enzymes (aminotransferases) and cell-death fragments (cytokeratin-18). Others come from the liver’s wound-healing scaffold, indicating scar turnover (hyaluronic acid, procollagen III peptide). Metabolic and inflammatory markers capture the forces driving the disease—insulin resistance and systemic inflammation (glucose–insulin indices, triglycerides, C-reactive protein). Together, these markers help estimate the presence of simple fat, active inflammation (steatohepatitis), and scarring, so clinicians can stage disease, monitor change over time, and judge response to lifestyle or medications. They also flag who needs imaging or specialist evaluation and help forecast complications like cirrhosis or cardiovascular risk, turning complex liver biology into actionable guidance.

Why are NAFLD biomarkers important?

NAFLD biomarkers are blood signals that show how your body is handling fat, sugar, and liver cell stress. Together, liver enzymes (ALT, AST, GGT) and lipid markers (triglycerides, HDL, LDL, ApoB, and the atherogenic index of plasma, AIP) map the traffic of fat from gut to liver to bloodstream and onward to the heart, linking liver fat to insulin resistance, inflammation, and vascular risk.

Typical lab limits place ALT and AST up to about 40, with true “healthy” upper limits often lower; GGT commonly runs up to about 60 and tends to be lower in women than men. For these enzymes, the most favorable values sit toward the low end, reflecting minimal hepatocyte injury and better bile flow. Triglycerides are generally “normal” under 150 and are metabolically best toward the low end; HDL is more protective when higher (often above 50 in women, 40 in men); LDL is safer lower (often under 100), and ApoB—an atherogenic particle count—is best lower (often under 80). AIP, the log of triglycerides/HDL, is optimal in the low or negative range; rising values signal insulin-resistant, small‑dense LDL patterns common in NAFLD.

When values run low: low ALT, AST, and GGT usually mean quiet liver turnover; symptoms are uncommon. Very low triglycerides often reflect efficient fat handling; very low LDL/ApoB can occur with genetic variants or undernutrition and may coexist with fatigue or weight loss if intake is poor. Low HDL is the exception—it reflects impaired reverse cholesterol transport and aligns with NAFLD and insulin resistance, more pronounced in men and in postmenopausal women. In pregnancy, triglycerides and HDL rise physiologically while GGT often falls; in children and teens, healthy ALT limits are lower than in adults.

Big picture: these markers integrate liver fat, endocrine signals, and cardiovascular risk. Persistent enzyme elevations and atherogenic lipids track with fibrosis progression, type 2 diabetes, and atherosclerosis, while favorable patterns indicate restored metabolic flexibility and lower long‑term risk.

What Insights Will I Get?

Nonalcoholic fatty liver disease (NAFLD) sits at the center of energy and lipid handling, linking liver fat to insulin resistance, cardiovascular risk, and systemic inflammation that can affect cognition, reproductive hormones, and immunity. At Superpower, we test ALT, AST, GGT, Triglycerides, HDL, LDL, ApoB, and AIP.

ALT and AST are liver-cell enzymes that reflect hepatocyte injury; GGT reflects cholestasis and oxidative stress. Triglycerides show how the liver packages and exports fat (VLDL). HDL represents reverse cholesterol transport. LDL carries cholesterol to tissues. ApoB is the count of atherogenic lipoprotein particles (VLDL/IDL/LDL). AIP, derived from the triglycerides-to-HDL ratio, indicates the tendency toward small, dense, more atherogenic LDL. In NAFLD, ALT and GGT often rise, triglycerides tend to be higher with lower HDL, LDL cholesterol may appear “normal” while ApoB is elevated, and AIP shifts higher.

When ALT/AST are stable and within reference, hepatocyte integrity is more likely preserved; elevations—especially with higher GGT—suggest active liver stress or steatohepatitis. Favorable triglycerides with higher HDL signal better lipid trafficking and insulin sensitivity. Lower LDL with low ApoB indicates fewer atherogenic particles and less hepatic overproduction of VLDL; a low AIP reflects larger, less atherogenic LDL and greater metabolic stability. Enzyme normality does not exclude liver fat, but discordant patterns (e.g., high ApoB/AIP with modest enzymes) point to cardiometabolic risk even without overt inflammation.

Notes: Interpretation varies with age, sex, pregnancy, ethnicity, fasting status, recent illness or strenuous exercise, alcohol, and medications (e.g., statins, fibrates, antiepileptics). Muscle injury can raise AST; thyroid and kidney disorders, viral hepatitis, and assay variability also influence results. Enzymes can be normal in NAFLD.